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Accumulating evidence suggests that active maintenance of optimal levels of the
essential pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is beneficial
in conditions of either increased NAD+ turnover or inadequate synthesis, including
Alzheimer’s disease and other neurodegenerative disorders and the aging process. While
studies have documented the efficacy of some NAD+ precursors such as nicotinamide
riboside (NR) in raising plasma NAD+, no data are currently available on the fate of
directly infused NAD+ in a human cohort. This study, therefore, documented changes
in plasma and urine levels of NAD+ and its metabolites during and after a 6 h
3 µmol/min NAD+ intravenous (IV) infusion. Surprisingly, no change in plasma (NAD+) or
metabolites [nicotinamide, methylnicotinamide, adenosine phosphoribose ribose (ADPR)
and nicotinamide mononucleotide (NMN)] were observed until after 2 h. Increased urinary
excretion of methylnicotinamide and NAD+ were detected at 6 h, however, no significant
rise in urinary nicotinamide was observed. This study revealed for the first time that:
(i) at an infusion rate of 3 µmol/min NAD+ is rapidly and completely removed from the
plasma for at least the first 2 h; (ii) the profile of metabolites is consistent with NAD+
glycohydrolase and NAD+ pyrophosphatase activity; and (iii) urinary excretion products
arising from an NAD+ infusion include NAD+ itself and methyl nicotinamide (meNAM) but
not NAM.
Keywords: NAD+, nicotinamide (NAM), ADP ribose, methyl nicotinamide, nicotinamide mononucleotide
INTRODUCTION
The parent pyridine nucleotide, nicotinamide adenine dinucleotide (NAD+) is present in all cells
of the body and is essential for cell viability and function.
As a cofactor responsible for electron transport into the respiratory chain, NAD+ and its
redox couple NADH are central to energy (ATP) production in the mitochondria via oxidative
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phosphorylation. The phosphorylated metabolite of NAD+,
NADP+ with its redox couple NADPH also provides the
reducing power to drive a number of anabolic reactions,
including cholesterol and nucleic acid synthesis, elongation
of fatty acids and regeneration of glutathione (GSH), one of
the body’s main antioxidants. Overall this family of pyridine
nucleotides, [NAD(P)(H)], contributes to the redox exchange
of over 400 enzyme reactions. Importantly, when acting as
a redox couple NAD+ is not consumed. However, NAD+
also serves as a substrate for a number of other important
metabolic processes and is therefore consumed as a consequence
of their chemical reactions, potentially depleting the tissue of
NAD+. Included in this number are reactions driven by the
poly adenosine phosphoribose-ribose (ADPR) family of enzymes
(PARP 1–17) controlling DNA repair and nuclear stability,
epigenetic control enzymes (Sirt1–7), intercellular immune
communication (CD38/CD157) and neuronal regeneration
(SARM1; Essuman et al., 2017). The potential exists therefore
for the disruption of cellular metabolism at multiple levels in
conditions where NAD+ consumption by these enzymes exceeds
NAD+ supply or synthesis.
The clinical importance of maintaining cellular NAD+ levels
was established early in the last century with the finding
that pellagra, a disease characterized by diarrhea, dermatitis,
dementia and death, could be cured with foods containing the
NAD+ precursor niacin (also known as vitamin B3; Goldberger,
1914). Although pellagra is rare in developed countries, cellular
concentrations of NAD+ have been shown to decrease under
conditions of increased oxidative damage such as occur during
aging (Braidy et al., 2011; Massudi et al., 2012; Guest et al.,
2014). Altered levels of NAD+ have been found to accompany
several disorders associated with increased oxidative/free radical
damage including diabetes (Wu et al., 2016), heart disease (Pillai
et al., 2005), age-related vascular dysfunction (Csiszar et al.,
2019), ischemic brain injury (Ying and Xiong, 2010), misfolded
neuronal proteins (Zhou et al., 2015) and Alzheimer’s dementia
(Abeti and Duchen, 2012).
In addition to the pathological hallmarks of Aβ plaques and
neurofibrillary tau tangles, oxidative damage is a consistent
finding in Alzheimer’s disease and is widely recognized as
an early event in the pathogenic process, even preceding Aβ
deposition (Su et al., 2008). While the reactive oxygen species
(ROS) causing this damage likely originate from multiple
sources, dysfunctional mitochondria and availability of redox
activemetals such as Fe++ and Cu+ are thought to play dominant
roles (Zhua et al., 2007).
A major consequence of cellular oxidative stress, in the
brain and elsewhere, are single or double stranded breaks to
the DNA. In response to DNA damage, PARP1 hydrolyzes
NAD+ to produce polymers of ADP-ribose (Ying, 2013). We
showed previously that NAD+ levels were inversely correlated
to measures of oxidative stress in human tissue (Massudi et al.,
2012) and in the rat brain (Braidy et al., 2014). Thus, while
reduced levels of NAD+ in the brain of living Alzheimer’s
sufferers awaits confirmation by non-invasive techniques the
consistent findings of oxidative damage in the post mortem
brain strongly supports the view that accelerated NAD+ turnover
and depletion contribute to the neurological dysfunction in this
disease. As interventions targeted at restoring NAD+ have been
shown in animal models to support healthy aging and improve
metabolic function (Yoshino et al., 2011; Mills et al., 2016) and
dementia (Long et al., 2015), strategies to raise NAD+ levels in
the human are being actively explored.
The most direct method of increasing NAD+ levels is
through intravenous (IV) administration. Though data from
experimental research is minimal, the significant clinical benefit
of IV NAD+ infusion in alcohol withdrawal has been previously
reported (O’Holleran, 1961; Mestayer, 2019). Surprisingly,
while the oral administration of NAD+ precursors such as
nicotinamide riboside (NR) or nicotinamide mononucleotide
(NMN) are being enthusiastically investigated for their impact
on NAD+ levels (Yoshino et al., 2011, 2018; Mills et al., 2016;
Airhart et al., 2017), the metabolic fate and pharmacokinetic
properties of IV NAD+ administration are yet to be reported
in humans. This study, therefore, presents for the first time the
changes in concentrations of NAD+ and its metabolites during
an IV infusion of NAD+ in a cohort of healthy male participants.
MATERIALS AND METHODS
Participants
Eleven (Test n = 8, Control n = 3) male participants aged
30–55 years were recruited via advertisements on radio, TV
and social media outlets. All participants had a BMI less than
30 kg/m2 (Test average BMI = 27.5 ± 2.5 kg/m2; Control
average BMI = 24.6 ± 6.5 kg/m2), were not diabetic, smoked
less than 1 cigarette and consumed less than 2 standard
alcoholic drinks per day. Individuals taking lipid lowering
or anti-inflammatory drugs, who had a history of liver or
renal failure or recently experienced a microbial infection,
trauma or any other significant or untreated medical disorders
were excluded from the study. Subjects received monetary
compensation for their time and participation, regardless of
whether they completed the experiment. Participants were not
permitted to use natural health products containing NAD+, NR
or Nicotinamide within 14 days prior to and during the course of
the study.
Diet Standardization
On the day prior to the NAD+ IV infusion participants
consumed an identical niacin-reduced diet and drank only water.
No food was consumed on the day of the study until after
the final 8 h blood/urine sample had been collected. Participants
were encouraged to drink water to remain normally hydrated. No
other beverage types were permitted.
To ensure adequate energy intake was maintained for
participants during the 6 h infusion the IV solution also
contained 0.1% dextrose, providing approximately 2,000 calories
over the 6 h infusion period.
Infusion Protocol
Participants were randomized to either the Test (n = 8) or
Control (n = 3) group. Participants in the Test group were
intravenously administered 750 mg NAD+ in normal saline
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(Archway Apothecary, Covington, LA, USA) over a 6 h period
(infusion rate = ∼2 mg/min ≡ 3 µmoles/min). This dosage of
NAD+ was derived empirically and reflects a common dosing
regimen in clinics (e.g., Springfield Wellness Clinic, Springfield,
LA, USA) which regularly provide IV NAD+ infusions in clinical
practice. Participants in the Control group were intravenously
administered normal saline over a 6 h period.
Clinical administration and supervision of the IV infusions
and sample collection were carried out at the Springfield
Wellness Center, Springfield, LA, USA.
Blood Sample Collection
Baseline (TO) blood samples were collected on all participants
after an overnight 12 h fast timed to occur immediately prior to
the start of the infusion. Additional samples were then collected
at 30, 60, 120 (2 h), 360 (6 h) and 480 (8 h) minutes after the start
of the infusion.
Whole blood was collected via standard venepuncture
(opposite arm to infusion site) into a 5 mL non-gel heparinized
tube. Immediately after the collection, the blood was centrifuged
at 4◦C for 10 min at 1,409× g.
The plasma and red blood cells fractions were immediately
separated and distributed into 5 × 500 µL aliquots each. All
aliquots were then immediately frozen and stored at −80◦C
until analysis.
Urine Sample Collection
After the collection of a baseline midstream urine sample,
participants were asked to void all urine into the receptacle(s)
provided at 30 min, 2 h, 6 h and 8 h after initiation of the NAD+
infusion. If participants needed to pass urine intermittently
between these time points they were asked to do so into the next
successive receptacle. All samples were aliquoted and stored at
−80◦C immediately upon receipt.
Analytical Method
Chromatographic separation of NAD+ and related metabolites
and MS detection Liquid chromatography coupled to tandem
mass spectrometry (LC/MS/MS) was carried out using a Sciex
QTRAP 5500 mass spectrometer (Sciex, Redwood City, CA,
USA) as previously described (Clement et al., 2018). Briefly,
100 µL of human plasma or urine was extracted in 400 µL
of ice-cold methanol, centrifuged at 4◦C for 10 min, and
filtered through 3 kDa membrane cartridges. Sample extracts
were dried under vacuum, reconstituted in 200 µL of 100 mM
NH4OAc buffer and transferred into 200 µL glass vials and
capped before LC/MS/ MS analysis. Standards and samples (20
µL) were injected onto a Phenomenex NH2 column (150 mm·
2 mm· 3 mm) as previously described. A binary solvent gradient
consisting of 5 mM NH4OAc pH 9.5 adjusted with ammonia
(mobile phase A) and acetonitrile (mobile phase B) with a flow
rate of 250 µL/min was used. Initial solvent composition at
injection was 25% A, followed by a 2-min gradient to 45% A and
a fast gradient ramp to 80% A (0.1 min) that was maintained for
5.9 min, A was increased again to 95% (2 min), held for 13 min,
and then reverted to initial conditions (0.1 min) for equilibration,
with a total run time of 30 min. The column flow was directed
into theMS detector. Calibration curves of individualmetabolites
were constructed using the peak area ratios (peak area of the
metabolite divided by peak area of the selected IS) of each
calibrator vs. its concentration.
Internal standards consisted of 2H2NAM (for NAM,
methylNAM and ADPR) and 13C5;-Cyclic AMP (for NMN
and NAD+). Note that as isotopic labels are not commercially
available for all NAD metabolites, a closely related molecule
(structural analog) can also be used (Yamada et al., 2006)
provided that it is deemed of similar stability and ionization
efficiency during analysis. The internal standards selected in this
study have been previously optimized for the related metabolite
(Bustamante et al., 2017).
Safety
The safety of IV NAD+ was assessed using liver function
tests and clinical observation of any adverse events. Liver
function tests consisted of serum, total bilirubin (bili), alkaline
phosphatase (ALP), alanine aminotransferase (ALT), gamma
glutamyl transferase (GGT), lactate dehydrogenase (LD) and
aspartate aminotransferase (AST).
Statistical Analysis
Statistical analysis was completed using SPSS version 24 and
GraphPad Prism version 8 for windows. An unweighted means,
two-way ANOVA with Bonferroni’s multiple comparison post
hoc test was used to determine if the mean concentration for
analysts tested were different over the 8 h period and between
Test and Control groups. The Wilcoxon Signed Ranks test was
used to determine if differences in mean liver function test
concentrations were significant between baseline and 8 h time
points. Differences were considered statistically significant when
p < 0.05.
Ethics
This study was carried out in accordance with The Code of Ethics
of the World Medical Association (Declaration of Helsinki) for
experiments involving humans. Ethical approval was obtained
from the William Carey University Institutional Review Board,
Hattiesburg, MS (Protocol #2017-12). Informed consent was
obtained from all participants.
RESULTS
Safety
No adverse events were observed during the 6 h infusion with
either placebo (saline) or test (NAD+) cohorts.
A significant decrease in activity (1.3, 57, 3.6 units/L) for
the liver function enzymes GGT, LD and AST, respectively was
observed at 8 h after initiation of the NAD+ infusion (Table 1).
No significant change in activity for any liver function marker
was apparent at 8 h in the placebo (saline) treated samples,
however low sample number may reduce discrimination
sensitivity. A significant increase of 2.75 µmoles/L in plasma
bilirubin was also observed. However, none of the changes were
considered clinically significant.
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TABLE 1 | The Wilcoxon Signed Ranks test was used to determine if differences in mean liver function test concentrations were significant between baseline and 8 h
time points.
Reference range Group Time 0 h Mean (SD) Time 8 h Mean (SD) p (T0 vs. T8)
Albumin (g/L) 36–47 Test 46.0 (2.5) 45.5 (2.9) ns
Control 44.3 (5.6) 42.0 (5.7) ns
Total protein (g/L) 64–83 Test 72.1 (4.3) 72.0 (4.5) ns
Control 76.3 (5.9) 73.7 (4.5) ns
Total bilirubin (µmol/L) 4–20 Test 9.3 (4.0) 12.0 (3.0) ≤0.05
Control 13.7 (5.5) 13.3 (4.0) ns
ALP (units/L) 35–110 Test 77.1 (23.9) 75.9 (21.9) ns
Control 67.7 (4.0) 62.7 (2.1) ns
ALT (units/L) 5–40 Test 40.8 (16.7) 38.9 (15.1) ns
Control 18.7 (4.9) 17.7 (4.0) ns
GGT (units/L) 5–50 Test 25.1 (17.4) 23.8 (16.9) ≤0.05
Control 23.3 (7.6) 21.7 (7.2) ns
LD (units/L) 20–250 Test 256.8 (66.3) 198.8 (78.0) ≤0.05
Control 133.3 (12.7) 146.3 (43.5) ns
AST (units/L) 10–40 Test 29.6 (6.7) 26.0 (6.7) ≤0.05
Control 22.0 (6.1) 21.7 (9.0) ns
Differences were considered statistically significant when p < 0.05.
Plasma
A continuous infusion of NAD+ at a rate of 3 µmoles/min
resulted in a significant (398%) increase in plasma NAD+ levels
only at the 6 h time point (i.e., end of infusion) relative to baseline
(p < 0.0001). This was significantly different from the 6 h saline-
treated control (p < 0.001).
NAD+ levels remained elevated at 8 h (i.e., 2 h post-infusion)
relative to baseline and saline treated control samples.
Plasma NAD+ levels did not change significantly from
baseline across the 8 h assessment period in saline treated control
samples (Figure 1A).
Similar to the changes observed for NAD+, plasma levels
of the NAD+ metabolite nicotinamide (NAM) increased
significantly by 409% at the end of the NAD+ infusion (i.e., 6 h)
relative to baseline (p < 0.0001). This was likewise significantly
different to the 6 h saline treated control (p < 0.001).
At the 8 h time point (i.e., 2 h after end of infusion), NAM
levels between the control and treated groups were no longer
significantly different (p > 0.05).
NAM levels for saline treated control samples did not change
significantly across the 8 h time period (p > 0.05, Figure 1B).
Consistent with the changes observed for NAM, plasma levels
of the NAD+ metabolite ADPR increased significantly by 393%
at the end of the NAD+ infusion (i.e., 6 h) relative to baseline
(p < 0.0001). This was significantly different to the 6 h saline
treated control (p < 0.0001).
At the 8 h time point (i.e., 2 h after the end of infusion),
ADPR levels remained 305% above baseline (p < 0.0001).
However, this was not significantly greater than ADPR levels
in the saline treated control samples at the same time
point (p > 0.05).
ADPR levels for saline treated control samples did not change
significantly across the 8 h time period (p > 0.05, Figure 1C).
A Spearman’s correlation analysis between group averages
across the 8 h time points for the two NAD+ catabolic
metabolites, NAM and ADPR, produced a correlation coefficient
of 1.00 (p < 0.001).
Again, consistent with the changes observed for NAM, plasma
levels of the NAM metabolite, methyl-nicotinamide (meNAM)
increased significantly to 350% at the end of the NAD+ infusion
(i.e., 6 h) relative to both baseline (p < 0.0001) and the 6 h saline
treated control (p < 0.01).
At the 8 h time point (i.e., 2 h after end of infusion)
meNAM levels remained 393% above baseline (p < 0.0001) and
significantly greater than the saline treated control samples at the
same time point (p < 0.05).
meNAM levels for saline treated control samples did not
change significantly across the 8 h time period (p > 0.05,
Figure 1D).
Plasma levels of NMN, a metabolite of NAM via the anabolic
salvage pathway, was significantly elevated (472%) only at the 8 h
time point (i.e., 2 h after end of infusion, p < 0.05).
NMN levels for saline treated control samples did not change
significantly across the 8 h time period (p > 0.05, Figure 1E).
Urine
The continuous IV infusion of NAD+ at a rate of 3 µmoles/min
resulted in a significant (538%) increase in the urine NAD+
excretion rate at the 6 h time point (i.e., end of infusion) relative
to that excreted at 30 min (p < 0.001). This was also significantly
different to the amount of urine NAD+ excreted at 6 h by the
saline treated controls (p < 0.05).
The amount of NAD+ excreted in urine decreased by 43%
(p < 0.05) at 8 h (i.e., 2 h post-infusion) relative to the peak
excretion at the 6 h time point.
The urine excretion rate for NAD+ did not change
significantly across the 8 h assessment period in saline treated
control samples (Figure 2A).
The excretion rate of the NAD+ metabolite NAM did not
change significantly across the 8 h test period and was not
different to the observed NAM excretion rate for the saline
treated controls (Figure 2B).
The urine excretion rate of the NAMmetabolite meNAMwas
significantly increased (403%) at the 6 h time point (i.e., end
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FIGURE 1 | Changes in plasma nicotinamide adenine dinucleotide (NAD+) and metabolites over 8 h [1st 6 h consisting of a continuous (3 µmoles/min) NAD+ IV
infusion]. (A) NAD+, (B) Nicotinamide (NAM), (C) adenosine phosphoribose (ADPR), (D) methyl nicotinamide (meNAM), (E) nicotinamide mononucleotide (NMN).
∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, as indicated. Two-way ANOVA with Bonferroni’s multiple comparison post hoc test was used to determine if
the mean concentration for analysts tested were different over the 8 h period and between Test (n = 8) and Control (n = 3) groups.
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FIGURE 2 | Changes in urine NAD+ and metabolites over 8 h (1st 6 h
consisting of a continuous, 3 µmoles/min, NAD+ IV infusion). (A) NAD+, (B)
NAM, (C) meNAM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, as
indicated. Two-way ANOVA with Bonferroni’s multiple comparison post hoc
test was used to determine if the mean concentration for analysts tested were
different over the 8 h period and between Test (n = 8) and Control (n = 3)
groups.
of infusion) relative to that observed at 30 min (p < 0.01).
The amount of meNAM excreted in urine decreased by 43%
(p < 0.05) at 8 h (i.e., 2 h post-infusion) relative to the peak
excretion at the 6 h time point.
The urine excretion rate for meNAM did not change
significantly across the 8 h assessment period in saline treated
controls (Figure 2C).
DISCUSSION
A growing interest in NAD+ based therapies including NAD+
infusions has highlighted the need for a clearer understanding
of the fate of NAD+ and its metabolites following IV
administration. The current study documents changes in levels
of NAD+ and key metabolites in both plasma and urine over
8 h using a typical clinical dosing regimen of 750 mg NAD+
administered IV over a 6 h period.
Importantly infusion of NAD+ did not produce any
observable adverse events in the test cohort but rather reduced
plasma activities of enzymes indicative of hepatic stress such as
the intrahepatic LD and AST and the post-hepatic (bile duct)
enzyme GGT suggesting that the integrity of both intra hepatic
and post-hepatic tissue was enhanced even within the relatively
short 8 h time frame. The rise in bilirubin, a red cell degradation
product, at 8 h may reflect either a very small increase in red
cell turnover, as can occur due to infusion induced hemeolysis,
or reduced heme metabolism (Table 1). However, given the
very low magnitude of this change, this was not considered
clinically relevant.
As expected, in saline-treated (i.e., control) participants,
plasma levels of NAD+ and metabolites NAM and ADPR and
the NAM metabolites, NMN and meNAM remained essentially
unchanged across the 8 h period. However, an apparent decrease
in NAM,meNAM and ADPRwere observed between 30min and
6 h, most likely due to a saline dilution effect. Consistent with this
notion, values for these analytes were seen to return to baseline
levels at 8 h (i.e., 2 h after the end of the saline infusion).
Unexpectedly however in NAD+ infused participants, plasma
NAD+ levels failed to rise until after the 2 h time point reaching
a maximum of∼400% above baseline for NAD+ and metabolites
NAM, meNAM and ADPR (398%, 409%, 393%, respectively)
only at the 6 h time point (Figures 1A–E). This was internally
consistent with the peak of urinary excretion for both NAD+ and
meNAM also occurring at 6 h before rapidly decreasing after the
end of the infusion (Figures 2A–C).
NAD+ was infused at a constant rate of 3 µmoles/min.
Therefore 90 µmoles of NAD+ was being infused directly into
the vascular compartment every 30min delivering a total of 1,080
µmoles by the end of the infusion at 6 h. Intravascular mixing
from any point of infusion occurs within ∼2 min; assuming an
average blood volume of 5, the added NAD+, in the absence
of significant metabolism or absorption, would correspond to
an additional rise in (NAD+) of at least 18 µM, every 30 min
across the 6 h of infusion. While an increase of this magnitude
is well within this study’s analytical detection limits no increase
in either NAD+ or its metabolites, were observed until after
2 h (i.e., at the 6 h time point) in either plasma or urine. This
unexpected observation indicates a rapid, and for at least the first
2 h, complete tissue uptake and/or metabolism of NAD+ and/or
its metabolites.
A number of enzymes can achieve effective NAD+ catabolism
including the sirtuins (SIRTs 1–7) the adenosine diphosphate
(ADP)–ribose transferases (ARTs) and poly(ADP-ribose)
polymerases (PARPs 1–17) and the cyclic ADP-ribose
(cADPR) synthases (CD38, CD157). Extracellular NAD+
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FIGURE 3 | Potential extracellular catabolism of exogenously supplied NAD+ through activity of ectoenzymes CD38 (ADP-ribose (ADPR) synthase), CD203a (NAD+
pyrophosphatase), CD 73 (5′-nucleotidase), CD157-ADP-ribosyl cyclase 2. Abbreviations: NAM, nicotinamide; NMN, nicotinamide mononucleotide; ADPR,
adenosine diphosphate riboside; meNAM, methyl nicotinamide; 4PY, N-methyl-4-pyridone-3-carboxamide; 2PY, methyl-2-pyridone-5-carboxamide; ARPP, ADP
ribose pyrophosphatase; RPPK, ribosyl pyrophosphokinase; NAmpt, nicotinamide phosphoribosyltransferrase; NMNAT, nicotinamide
mononucleotideadenyltransferase; CX-43, connexin 43.
pyrophosphatases present in human serum can also degrade
NAD+ to AMP and NMN (Schmidt-Brauns et al., 2001). The
cell-surface protein CD73 also converts NMN into NR, which
easily crosses cell membranes for potential resynthesis to NAD+.
Importantly the NAD+ catabolizing glycohydrolases, CD38 and
CD157, ecto-nucleotide pyrophosphatase (CD203a) and the
NMN catabolizer CD73 are ectoenzymes found on a wide
variety of cells including lymphoid, granulocytic, neuronal and
endothelial cells (Wei et al., 2014) and plasma soluble NAD
glycohydrolases may also be present (Figure 3; Funaro et al.,
2009). The parallel rise of plasma NAM and ADPR (correlation
coefficient of 1.000, p < 0.001, data not shown) strongly
suggests that at least by 6 h a major fate of NAD+ is metabolism
through cleavage of the glycosidic ADPribose–nicotinamide
linkage to NAM and ADPR, by-products symptomatic of
NAD glycohydrolase (e.g., CD38) activity. This is consistent
with evidence by others where CD38, in particular, has been
shown to have a primary role in controlling extracellular
NAD+ levels (Wei et al., 2014). Adult human erythrocytes are
CD38 positive and express high levels of NAD+ glycohydrolase
activity, cleaving exogenous NAD+ to supply erythrocytes
with ADP ribose that can be efficiently taken up into the cell
(Kim et al., 1993; Albeniz et al., 2004). The absence of any
rise in either NAD+ or metabolites, in plasma or urine, until
after the first 2 h of the infusion indicates that NAD+ and/or
its metabolites are trafficked out of the extracellular vascular
space and efficiently sequestered into tissue or extravascular
compartments as NAD+ and/or its metabolites during this
time period.
Though PARP and sirtuins are involved in NAD+ catabolism,
as intracellular enzymes with representatives in cytoplasm,
nucleus and mitochondria they are unlikely to directly impact
extracellular NAD+ levels. However, these enzymes may be
expected to respond to changes in intracellular concentrations of
NAD+, NAM and NR that may arise from exogenously supplied
NAD+. Figure 4 summarizes schematically the possible fates of
exogenous NAD+.
While significant capacity exists for the rapid degradation of
the exogenously supplied IV NAD+ into constituent metabolites,
it is also worth noting that uptake of extracellular NAD+
may also be occurring. As NAD+, has an overall negative
charge it is unable to cross cellular membranes passively and
therefore must be actively transported across the membrane.
That this occurs has been shown by a number of researchers
who have reported that exogenous NAD+ applied to a variety
of human cell types does indeed result in a significant elevation
of intracellular NAD+ (Ying et al., 2003; Zhu et al., 2005;
Billington et al., 2008; Pittelli et al., 2011; Felici et al.,
2013). While the mechanism(s) involved are not yet fully
characterized, Alano et al. (2010) reported that exogenous
NAD+ could enter neurons through P2X7 gated channels
and others have consistently observed the transport of NAD+
across membranes by connexin 43 (CX43) hemichannels, even
at concentrations as low as 250 pM (Billington et al., 2008).
As connexins have a wide distribution in human tissue and
CX43 appears to be the most ubiquitous connexin in many
cell types the potential for rapid uptake of NAD+ cannot
be discounted.
Thus cellular uptake and/or metabolism of NAD+ and
metabolites NAM and ADPR and secondary metabolites
meNAM and NMN appeared to proceed at pace with the
3 µmoles/min NAD+ infusion for at least the first 2 h.
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FIGURE 4 | Potenital Intra and extracellular fate of exogenously supplied NAD+. Abbreviations: CD38 [cyclic ADP-ribose (cADPR) synthase], CD203a (NAD+
pyrophosphatase), CD 73 (5′-nucleotidase). NAM, nicotinamide; NMN, nicotinamide mononucleotide; ADPR, adenosine diphosphate riboside; meNAM, methyl
nicotinamide; 4PY, N-methyl-4-pyridone-3-carboxamide; 2PY, methyl-2-pyridone-5-carboxamide; ARPP, ADP ribose pyrophosphatase; RPPK, ribosyl
pyrophosphokinase; NAmpt, nicotinamide phosphoribosyltransferrase; NMNAT, nicotinamide mononucleotideadenyltransferase; PARP [poly ADPribose polymerase;
SIRT [sirtuin]; NRK [nicotinamide riboside kinase].
Either NAD+ and/or the primary metabolites tested are being
efficiently sequestered during this first 2–6 h period or secondary
metabolites are also being formed. ADPR can be recycled to
produce NAD+ from NAM (Figure 4) or further metabolized
via ectoenzymes such as CD203a (NAD+ pyrophosphatase)
to produce AMP which can be further rapidly metabolized
to adenosine by CD73 a 5′-nucleotidase (Bogan and Brenner,
2010; Horenstein et al., 2016; Morandi et al., 2018). In support
of this hypothesis, an increase in blood adenosine levels has
been recognized by others as a consequence of extracellular
NAD+ infusion (Szczepañska-Konkel et al., 2003). NAM can
also be metabolized to NMN via the salvage pathway before
resynthesis to NAD+ (Figures 3, 4) or acted on by hepatic
methyltransferases to produce N1-methylnicotinamide which
may either be excreted directly or further converted to N-
methyl-2-pyridone-5-carboxamide (2PY, +99% of meNAM)
and N-methyl-4-pyridone-3-carboxamide (4PY, ∼0.25% of
meNAM) before excretion (Shibata and Matsuo, 1989; Okamoto
et al., 2003).
It is evident that at the dosing regimen used the mechanisms
involved in the metabolism and sequestering of NAD+ and
metabolites have reached saturation sometime after 2 h resulting
in a significant elevation of plasma NAD+ and accumulation of
all metabolites tested (NMA, ADPR, meNAM and NMN) at 6 h.
As mentioned previously these data support the view that one
major pathway for NAD+ metabolism under these conditions
is the cleavage of the glycosidic bond, by ectoenzymes such as
CD38 to produce NAM and ADPR. However, the rise in plasma
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NMN after 2 h also suggests that exogenous NAD+ is likely acted
on by extracellular NAD+ pyrophosphatases, elevating plasma
NMN and releasing AMP as an additional metabolite.
In summary, this study revealed for the first time that: (a)
at a flow rate of 3 µmole/min all exogenously infused NAD+
was rapidly and completely removed from the plasma for at
least the first 2 h; (b) the increase in metabolic bi-products
analyzed is consistent with NAD+ glycohydrolases and NAD+
pyrophosphatase activity; and (c) the urinary excretion products
arising from NAD+ infusion include native NAD+ and meNAM
but not NAM.
While the findings of this investigation are novel and go
some way to advancing our understanding of the timed fate
of exogenous NAD+ in humans, limitations were identified.
To improve overall metabolic reckoning future studies should
investigate changes in red cell NAD+ and metabolites and
urinary excretion of the secondary meNAM metabolites, 2PY
and 4PY. In addition, it will likely be useful to assess the
impact of exogenous NAD+ on changes in purine metabolism
which should include at least assessment of plasma and red
cell AMP and adenosine. The use of animal models may also
help to clarify the relative involvement of the various metabolic
pathways through the use of suitable pharmacological inhibitors
and tissue sampling.
In conclusion, this study was able to reveal for the first
time some very useful, previously unknown, information about
the fate of exogenous IV NAD+ in humans including, the
overall safety and tolerability of an IV NAD+ infusion at a rate
of 3 µmoles/min, the rapid sequestering of NAD+ from the
plasma, the likely contribution of both NAD+ glycohydrolase
and NAD+ pyrophosphate activity in the metabolism of
NAD+ and the apparent efficient renal tubular reabsorption
of NAM. However additional research is required to fully
reveal the complex metabolic fate of this important molecule.
Further, characterization of these changes will help progress
the development and improvement of NAD+ based treatment
regimens for disorders which are likely to benefit from increased
NAD+ availability including conditions requiring increased
cellular regeneration and repair such as Alzheimer’s and other
neurodegenerative dementias.
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